About Solvonis Therapeutics
Solvonis Therapeutics is a company based in London (United Kingdom) founded in 2017 by Victor Bolduev and Anthony Tennyson. Solvonis Therapeutics has completed 1 acquisition, including AWAKN. Solvonis Therapeutics offers products and services including Novel Medicines and AI-Supported CNS Programmes.
- Headquarter London, United Kingdom
- Founders Victor Bolduev, Anthony Tennyson
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Solvonis Therapeutics Plc
-
Annual Revenue
Not available
-
Net Profit
-$1.99 M (USD)49.04as on Dec 31, 2024
-
EBITDA
-$1.89 M (USD)25.75as on Dec 31, 2024
-
Latest Funding Round
$1.67 M (USD), Post-IPO
Oct 16, 2025
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Solvonis Therapeutics
Solvonis Therapeutics is a publicly listed company on the LSE with ticker symbol SVNS in UK, operating in the Producer manufacturing sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Solvonis Therapeutics
Solvonis Therapeutics offers a comprehensive portfolio of products and services, including Novel Medicines and AI-Supported CNS Programmes.
Medicines for addiction and mental health disorders are developed to address treatment limitations.
AI-supported programmes for CNS compounds are utilized in the discovery of new therapeutics.
Funding Insights of Solvonis Therapeutics
Investments & Acquisitions by Solvonis Therapeutics
Solvonis Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AWAKN.
Investment portfolio details for Solvonis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRO focused on early stage clinical trial research
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Solvonis Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Solvonis Therapeutics
Detailed financials for Solvonis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Solvonis Therapeutics Comparisons
Peer comparison for Solvonis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Solvonis Therapeutics
Detailed competitors of Solvonis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solvonis Therapeutics
Complete news archive for Solvonis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Solvonis Therapeutics
Solvonis Therapeutics was founded in 2017 and raised its 1st funding round 8 years after it was founded.
Solvonis Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Anthony Tennyson is the current CEO of Solvonis Therapeutics. They have also founded this company.
Solvonis Therapeutics was founded in 2017 in London, United Kingdom. Operations center on the biotechnology sector, where new medicines are developed to treat addiction and mental health disorders. Initial efforts are directed toward post-traumatic stress disorder, addressing gaps in current treatments. Patient outcomes are targeted for improvement, alongside reductions in associated societal and economic impacts. The companys domain is solvonis.com.
Solvonis Therapeutics offers Novel Medicines and AI-Supported CNS Programmes.
Yes, Solvonis Therapeutics is publicly traded on LSE under the ticker symbol SVNS.
Solvonis Therapeutics has made 1 acquisition, including AWAKN.
The ticker symbol of Solvonis Therapeutics is SVNS on LSE.